TrialThe oncologist2020
Health-Related Quality of Life in MONARCH 2: Abemaciclib plus Fulvestrant in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer After Endocrine Therapy.
Peter A Kaufman et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
45 papers cite it
this paperpooled ittrialcites it